| pubmed-article:11738480 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11738480 | lifeskim:mentions | umls-concept:C2754100 | lld:lifeskim |
| pubmed-article:11738480 | lifeskim:mentions | umls-concept:C0165264 | lld:lifeskim |
| pubmed-article:11738480 | lifeskim:mentions | umls-concept:C0348080 | lld:lifeskim |
| pubmed-article:11738480 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:11738480 | pubmed:dateCreated | 2001-12-12 | lld:pubmed |
| pubmed-article:11738480 | pubmed:abstractText | Cortical cells from embryonic mice (E17) showed a rapid cell-death under the serum-free condition. The addition of nefiracetam at 0.1-10 microM increased the survival activity, while aniracetam at the same concentrations did not. The cell death was characterized to be apoptotic, since dead cells showed nuclear condensation, fragmentation, and TUNEL-positive staining. The nefiracetam-induced anti-apoptotic activity was completely blocked by 1 microM nifedipine or omega-conotoxin GVIA, and partially by 1 microM verapamil. These results suggest that the reported anti-amnesic action of nefiracetam in ischemic animals may be partly attributed to the neuroprotective action. | lld:pubmed |
| pubmed-article:11738480 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11738480 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11738480 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11738480 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11738480 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11738480 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11738480 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11738480 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11738480 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11738480 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11738480 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11738480 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11738480 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:11738480 | pubmed:issn | 0197-0186 | lld:pubmed |
| pubmed-article:11738480 | pubmed:author | pubmed-author:FujitaRyousuk... | lld:pubmed |
| pubmed-article:11738480 | pubmed:author | pubmed-author:TakayamaNaoko... | lld:pubmed |
| pubmed-article:11738480 | pubmed:author | pubmed-author:UedaHiroshiH | lld:pubmed |
| pubmed-article:11738480 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11738480 | pubmed:volume | 40 | lld:pubmed |
| pubmed-article:11738480 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11738480 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11738480 | pubmed:pagination | 139-43 | lld:pubmed |
| pubmed-article:11738480 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:meshHeading | pubmed-meshheading:11738480... | lld:pubmed |
| pubmed-article:11738480 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11738480 | pubmed:articleTitle | The cognition-enhancer nefiracetam is protective in BDNF-independent neuronal cell death under the serum-free condition. | lld:pubmed |
| pubmed-article:11738480 | pubmed:affiliation | Department of Molecular Pharmacology and Neuroscience, Nagasaki University School of Pharmaceutical Sciences, 1-14 Bunkyo-Machi, Nagasaki 852-8521, Japan. | lld:pubmed |
| pubmed-article:11738480 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11738480 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
